查看文章

Background: Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. However, adverse events related to the immunosuppressive properties of these biologics have been observed.

Methods: This review aims to synthesize and evaluate the literature investigating the risk of HZ in patients treated with IL-17 inhibitors, with a focus on psoriasis patients. We performed searches using the PubMED database with the following search terms:‘psoriasis,’‘herpes zoster,’‘secukinumab,’‘ixekizumab,’‘brodalumab,’‘IL-17,’‘anti-IL-17,’and ‘safety.’Clinical trials, cohort studies, review articles, and meta-analyses were evaluated.

Results: Studies did not detect a higher risk of HZ infections in psoriasis patients treated with …